上海翻译公司完成解说词英文翻译

一、历史与荣耀history and honor

在中国，“北京协和”，早已成为值得信赖的象征和家喻户晓的品牌。北京协和药厂，隶属于中国医学科学院药物研究所，创立于1958年.秉承严谨的科技创新精神，经过半个多世纪的发展，北京协和药厂已成为北京市高新技术企业、“瞪羚计划”首批重点培育企业、标准创新试点单位和北京市专利示范单位，并纳入中央国有资本经营预算实施范围。依托中国医学科学院药物研究所的强大研发实力，北京协和药厂先后上市了多个拥有自主知识产权的原研产品，是国内为数不多的有原研化学药物制剂出口海外的制药企业，以多个原研药物为代表的“协和”品牌，已成为民族制药业“中国创造”的典范。北京协和药厂不仅承担着企业自身发展的重任，还立志推动中国民族制药业的进步与发展，每个协和人为之奋斗、为之自豪！

In China, ‘Beijing Union’ has been a famous and trustworthy brand for quite a long time. Beijing Union Pharmaceutical Factory was founded in 1958 and is subordinate to Institute of Materia Medica (IMM), Chinese Academy of Medical Sciences & Peking Union Medical College. With the spirit of rigorous technology innovation in the development forAfter more than half-century, it has been listed as a new & high-tech enterprise in Beijing City, one of the first cultivated high-growth medium-sized and smallmedium-and-small-sized enterprises, standard innovation pilot unit and Beijing patent demonstration unit it was incorporated into the scope of central state-owned capital management budget implementation. Depending on strong innovation and research strength from IMM, we focus on creation and production of innovative drugs with proprietary intellectual property rights. It is one of few Chinese factories who export its innovative chemical preparations. Presented by multiple innovative drugs, “Union” brand has been the sample of “created in China” in national pharmaceutical industry. With its development, the factory also promotes progress and development for national pharmaceutical industry, for which every staff of “Union” has been striving for and proud of. .

 

二、发展与优势Development and Strength

五十余年来，秉承“以质量求生存，以科技创新求发展，为人类的健康事业作贡献”的企业宗旨，北京协和药厂已经从肇建之始的新药中试基地成长为集研发、生产、营销为一体的高科技制药企业。

It was just a new drug pilot plant fifty years ago, but now it becomes a new & high-tech enterprise with tenet of "surviving by good quality, seeking development by innovation and making a contribution to improve contributing to improving human health", covering business scope of medical research R&D, production and marketing.

1、              强大的研发与产业化实力  北京协和药厂建有北京市企业技术中心，先后承担完成国家高技术产业发展项目、国家“863”计划项目、北京市高新技术成果转化项目、北京市工业发展资金项目等国家级、省部级新药研发和产业化专项。“双环醇的研究”更是获得了“2007年度国家科技进步二等奖”的殊荣。“十一五”期间，药厂又承担或参与了三项国家“重大新药创制”科技重大专项课题，进一步全面提升了企业自主创新及科研成果产业化能力。

1. Strong strength in research and industrialization

In addition, The the factory also has  an enterprise technology R&D center; we have undertakenundertake and accomplished some important national and provincial levels projects on new drug research and industrialization, such as national high technology industry development project, national ‘863’ plan poject’, Beijing high-tech achievement transformation project, Beijing industry development fund project, etc. “BICYCLOL RESEARCHThe research on Bicyclol” was awarded second National Prize for Progress in Science and Technology in 2007. During “Eleventh Five-year Plan” period, we undertook and participated in three science and technology subjects of national "major new drug creation" projects, which comprehensively upgraded the capacityability of enterprise independent innovation and industrialization of research findings.

 

2、              完善的质量保证控制体系  北京协和药厂拥有完善的质量保证和质量控制体系，建有通过国家GMP认证的多个化学原料药及片剂、胶囊剂、滴丸剂、乳膏剂、小容量注射剂、冻干粉针剂等多种剂型生产线，并通过ISO 14001环境管理体系认证和北京市清洁生产审核。

2. Perfect quality control system

We established perfect quality assurance and quality control systems, all production lines for chemical bulk drug, tablets, capsules, pills, creams, small volume injections (including anti-tumor class) and freeze-dried powder injections (antineoplastic agents) have got China GMP certification, as well as ISO 14001 Environment Management System Certification and Beijing Clean Production Audit.

3、              创新原研的产品系列  依托国家级新药研究机构——中国医学科学院药物研究所强大的药物研发实力，北京协和药厂致力于引进和开发具有高科技含量和自主知识产权的创新药物，陆续上市了多个世界首创的原研品种，如百赛诺 (双环醇片)、甲异靛片、联苯双酯滴丸、葛根素注射液、三尖杉酯碱注射液、高三尖杉酯碱注射液、灵孢多糖注射液、酞丁安乳膏等，产品囊括了抗肝炎药系列、抗肿瘤药系列以及心脑血管药系列等。其中，百赛诺——我国第一个上市的具有国际自主知识产权的一类化学新药，由中国医学科学院药物研究所创制、北京协和药厂独家生产，2001年上市并享有12年新药保护期。该药适用于伴有氨基转移酶升高的慢性病毒性肝炎和非病毒性肝病的保肝抗炎治疗，是中华医学会《慢性乙型肝炎防治指南》、《酒精性肝病诊疗指南》和《非酒精性脂肪性肝病诊疗指南》的推荐用药，列入《中国高新技术产品目录》、国家及各省级《基本医疗保险、工伤保险和生育保险药品目录》和《军队合理医疗药品目录》。

3. Innovative productsInnovation products serious

Depending on strong innovative resource and scientific research strength from IMM, we focus on introduction and development of innovative drugs with high-tech content and proprietary intellectual property rights. We launched many innovative drugs which were firstly put in the market internationally, including a series serious of anti hepatitis, antineoplastic and cardiovascular drugs, such as Bicyclol Tablets, Meisoindigo Tablets, bifendate pilules, harringtonine injection, Homoharringtonine injection, Polysaccharidum of G. Lucidum Karst Injection and Ftibamzone cream. Among these drugs, Bicyclol tablets were launched in 2001 and have 12 years of new drug protection period. Bicyclol was created by IMM and produced by Beijing Union Pharmaceutical Factory exclusively, which was the first Chinese innovated chemical drug with international independent intellectual property right in China. Bicyclol is suitable for the treatment of chronic viral hepatitis associated with elevated serum transaminase abnormalities and non viral liver disease. Bicyclol is listed in <Alcoholic liver disease diagnosis and treatment guidelines>, < Nonalcoholic fatty liver disease diagnosis and treatment guidelines >, < Chronic Hepatitis B Prevention and Control Guideline> issued by Chinese Medical Association, and inlisted into <China’s high-tech Products Directory>, and < The National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drug Catalogue, Catalogue of Drugs for Reasonable Military Medical Treatment. >.

 

4、              专业的学术推广  针对产品的学术推广，北京协和药厂在全国建立起一支专业、规范、高效的营销队伍，以临床需求为导向，以产品特性为核心，以客户服务为保障，获得了临床医生的广泛认可。优良的产品质量和高端的国际交流也为北京协和药厂进军海外市场开辟了通道。目前，百赛诺、联苯双酯滴丸、酞丁安乳膏等产品已登陆乌克兰、哈萨克斯坦、乌兹别克斯坦、韩国、埃及、越南、缅甸等国家，成为中国化学药品制剂走向国际的典范，获得了海外众多医患的赞誉。

4. Professional academic promotion

We have a professional well-behaved marketing team with high efficiency in China for academic promotion of products., Now many products have been widely acknowledged by clinicians.

With quality advantages of products and international high-end communications, Bicyclol tablets, bifendate pills and Ftibamzone cream have been sold domestically and internationally, including in Ukraine, Kazakhstan, Uzbekistan, Kyrghizstan, Tadzhikistan, Georgia, Egypt, Republic of Korea, Viet Nam and Myanmar, etc.

三、愿景与展望Vision and Prospect

立足国内，放眼海外，致力打造“中国创造”品牌，北京协和药厂以百赛诺作为龙头产品，近五年的净利润复合增长率超过40%。

We will keep Bicyclol as our flagship product to build the brand of ‘created in China’ home and abroad, and for five years have accompishedearn more than 40% of compound growth rate of net profits by more than 40%.

根据企业长远发展的需要，北京协和药厂斥资5亿元，在中关村科技园区大兴生物医药产业基地建设全新厂区，预计于2014年年底前全部投入使用，届时将建成国内领先、与国际接轨、达到欧盟GMP要求的现代化药品生产基地。

According to enterprise long-term development requirement, we are building a brand new plantproduction base in Daxing Biomedical Industry Base of Zhongguancun Science and Technology Park  the area of both Zhongguancun national Independent innovation demonstration zone and Beijing Bio-Engineering and Pharmaceutical Industrial Base. In the end of 2014, when it is put into service, it will be a modern pharmaceutical production base, in line with international standards and reach the EU GMP requirements.

此外，双环醇新型制剂、双功能紫杉醇共缀物、S1P1受体选择性激动剂、用于治疗老年性痴呆的天麻苄醇酯苷、抗焦虑药布格呋喃等创新药物的研发近期有望取得突破，将为企业的可持续发展增添更多新的动力。

In addition, some of new drug research and development projects will make a breakthrough recently, including new preparation of Bicyclol, bifunctional paclitaxel altogether compose objects, S1P1 selective agonist receptor, Gastrodia elata benzyl alcohol ester glycosides for treatment for senile dementia, antianxietic Bouguer furan, etc., which will add more new momentum for the enterprise's sustainable development.

 

{药物研究所蒋建东所长专访：

中国医学科学院药物研究所下辖北京协和药厂、北京协和制药二厂、北京联馨药业有限公司、北京协和建昊医药技术开发有限责任公司、国家新药开发工程技术研究中心等产业实体，涵盖了新药创制上下游从药物开发、评价、中试放大到产业化的较为完整的产业链条，在产学研资源、技术的整合，建立“以企业为主体”“产学研结合”的新药创制体系方面具有优良的传统和独到的优势。

Exclusive interview to president of IMM: There are several IMM-owned enterprises manufacturing drug products and providing technical services. They are Beijing Union Pharmaceutical Factory, Beijing Union Second Pharmaceutical Factory, Beijing LianXin Pharmaceutical Co., Ltd., Beijing Union Jianhao -Genius Pharmaceutical Development Technology Co., Ltd.,Chinese National New Medicine Development Engineering Research Center Beijing Collab Pharma Co., Ltd. All of them have formulated a complete industry chain covering new medicine R&D, evaluation, pilot-scale experiment and production. In general, IMM has fine traditions and unique advantages in integration of  industry-university-research cooperation resources and technology to establishing new medicine creation system in enterprises. through combination of basic research and R&D application, IMM serves the nation and patients with new drugs as well as industrial drug production. 

 

“十二五”期间，依托中国医学科学院药物研究所的技术与人力资源，我们将整体投资15亿元在中关村科技园区大兴生物医药产业基地建设“中国医学科学院药物研究所创新药物产学研基地”，项目的主要特点为：企业为主、校企共建、开放共享。我们将整合中国医学科学院药物研究所产学研技术及资源优势，按照国际新药创制的通行做法，打造一流的产业化基地以及产学研共建的平台，真正建立由企业带动科研机构、以市场为导向、产学研紧密结合的创新药物研究开发模式，提高集成创新能力，提高新药研发的效率，建立真正意义上的产业联盟，加快创新药物的产业化进程。

During the 12th Five-year Plan period, we, with the help of technology and human resource of IMM, will invest 1.5 billion yuan to build an industry-university-research cooperation base of innovative medicine, which is attached to IMM, in Daxing Biomedical Industry Base of Zhongguancun Science and Technology Park. The main feature of the project is that it will be co-constructed by enterprise and university while be played by enterprise. We will integrate technology and resource advantages of IMM, follow the international routine practiced in new medicine creation, and forge the first-rate industrialized base and platform for industry-university-research cooperation. Based on the marked-oriented, enterprise-driven and industry-university-research cooperated mechanism, it is actually hoped to establish a development model for innovative medicine research to enhance innovative capacity and R&D efficiency and to speed up industrialization of innovative medicine by building up industry alliance.

an innovative drug production base combining R&D, with total investment of 1.5 billion RMB. 

dedicate to innovation and development, maintain positive and steady operation, to build modern manufacturing sites for Beijing Union Pharmaceutical Factory and Beijing Union Second Pharmaceutical Factory, and a industry-university-research cooperation base of innovative drugs for IMM in the area of both Zhongguancun national Independent innovation demonstration zone and Beijing Bio-Engineering and Pharmaceutical Industrial Base

with the market-driven economy,

同时，北京协和药厂正在探索实施企业改制，引入新的经营思路，构建全新的运营机制，以进一步提升企业的核心竞争力。深入贯彻科学发展观，着力强化企业技术创新主体地位， 深化科技体制改革，是中国医学科学院药物研究所及其下属企业义不容辞的责任！}

Beijing Union Pharmaceutical factory is exploring restructuring of enterprise to introduce new management idea and construct new operational mechanism to enhance core competitiveness further. To strengthen technological innovation in enterprise and to deepen institutional reform of science and technology, which are also in line with Scientific Outlook on Development, are obligatory duties for IMM and its subordinate enterprises. 

体制的改革必将带来企业更快的发展，展望“十二五”，北京协和药厂将紧紧围绕改革、创新、发展的主题，与药物研究所共建国内领先水平的“创新药物产学研基地”，把握医药产业政策导向，实现国有资产持续增值，跻身先进制药企业行列，为国家实现医药强国的重大战略做出更新、更大的贡献！

Institutional reform will bring faster development for the enterprises. During the 12th Five-year Plan period, by following the theme of reform, innovation and development, we will build ana industry-university-research cooperation base of innovative drugs together with IMM, and achieve steady increase in value for the state-owned assets. It is hoped that we could stand in the advanced pharmaceutical enterprises and make a great contribution to the national grand strategy of becoming an international medical power.

t
上海翻译公司完成解说词英文翻译